Trial record 1 of 1 for:    NCT00796653
Previous Study | Return to List | Next Study

Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease II

This study has been completed.
Information provided by:
Boehringer Ingelheim Identifier:
First received: November 21, 2008
Last updated: May 4, 2011
Last verified: May 2011

The primary objective of this study is to assess the long-term efficacy and safety of once daily treatment of BI 1744 CL inhalation solution (5 and 10 mcg) delivered via the Respimat® inhaler, in patients with COPD.

Condition Intervention Phase
Pulmonary Disease, Chronic Obstructive
Drug: Olodaterol (BI 1744)
Drug: Formoterol
Drug: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Randomised, Double-blind, Double-dummy, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of 48 Weeks of Once Daily Treatment of Orally Inhaled BI 1744 CL (5 µg [2 Actuations of 2.5 ug] and 10 ug [2 Actuations of 5 ug]) Delivered by the Respimat® Inhaler, and 48 Weeks of Twice Daily Foradil® (12 µg) Delivered by the Aerolizer® Inhaler, in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Resource links provided by NLM:

Further study details as provided by Boehringer Ingelheim:

Primary Outcome Measures:
  • There are 3 co primary endpoints: FEV1 AUC 0 to 3hr response, trough FEV1 response and the Mahler TDI ) [ Time Frame: 24 Weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • St George's Respiratory Questionnaire at selected time points [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]
  • Mahler Dyspnoea Indices at selected timepoints [ Time Frame: 48 Weeks ] [ Designated as safety issue: No ]
  • Patient's Global Rating at selected timepoints [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]
  • COPD Exacerbations [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]
  • Adverse Events [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]
  • Vital Signs Pre dose and upto 3 hours post dose at selected timepoints [ Time Frame: 48 Weeks ] [ Designated as safety issue: No ]
  • Routine Blood Chemistry, hematology and urinalysis at selected timepoints [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]
  • 12 Lead ECG and Holter Monitoring (Patient subset) at selected timepoints [ Time Frame: 48 Weeks ] [ Designated as safety issue: No ]
  • FEV1 Pre dose and upto to 3 hours post dose at selected timepoints [ Time Frame: 48 Weeks ] [ Designated as safety issue: No ]
  • Forced Vital Capacity Pre dose and upto to 3 hours post dose at selected timepoints [ Time Frame: 48 Weeks ] [ Designated as safety issue: No ]
  • Peak Expiratory Flow Rates Pre dose morning and evening [ Time Frame: 48 Weeks ] [ Designated as safety issue: No ]
  • Number of Puffs of rescue medication used per day [ Time Frame: 48 Weeks ] [ Designated as safety issue: No ]

Enrollment: 937
Study Start Date: January 2009
Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Olodaterol (BI 1744) Low
Low dose inhaled orally once daily from the Respimat inhaler
Drug: Olodaterol (BI 1744)
Comparison of low and high doses on efficacy and safety in COPD patients
Experimental: Olodaterol (BI 1744) High
High dose inhaled orally once daily from the Respimat inhaler
Drug: Olodaterol (BI 1744)
Comparison of low and high doses on efficacy and safety in COPD patients
Active Comparator: Formoterol 12mcg
12mcg inhaled twice daily from the Aerolizer inhaler
Drug: Formoterol
Active comparator with Olodaterol (BI 1744) on safety and efficacy in COPD patients
Placebo Comparator: Placebo
Olodaterol (BI 1744) placebo inhaled once daily from the Respimat inhaler and/or Formoterol placebo inhaled twice daily from the Aerolizer inhaler
Drug: Placebo
Placebo devices for comparison with Olodaterol (BI 1744) on safety and efficacy in COPD patients


Ages Eligible for Study:   40 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion criteria:

  1. All patients must have a diagnosis of chronic obstructive pulmonary disease and must meet the following spirometric criteria:post-bronchodilator FEV1<80% of predicted normal (ECSC) and a post-bronchodilator FEV1/FVC <70% at Visit 1
  2. Male or female patients, 40 years of age or older
  3. Patients must be current or ex-smokers with a smoking history of more than 10 pack years:

Exclusion criteria:

  1. Patients with clinically relevant abnormal baseline haematology, blood chemistry, or urinalysis; all patients with an SGOT >x2 ULN, SGPT >x2 ULN, bilirubin >x2 ULN or creatinine >x2 ULN
  2. Patients with a history of asthma and/or total blood eosinophil count greater than 600/mm3
  3. Patients with thyrotoxicosis, paroxysmal tachycardia (>100 beats per minute)
  4. Patients with a history of myocardial infarction within 1 year of screening visit, unstable or life-threatening cardiac arrhythmia, hospitalization for heart failure within the past year, known active tuberculosis, a malignancy for which patient has undergone resection, radiation therapy or chemotherapy within last five years, life-threatening pulmonary obstruction, cystic fibrosis, clinically evident bronchiectasis, significant alcohol or drug abuse
  5. Patients who have undergone thoracotomy with pulmonary resection
  6. Patients being treated with oral beta-adrenergics or oral corticosteroid medication at unstable doses (i.e., less than six weeks on a stable dose) or at doses in excess of the equivalent of 10 mg of prednisone per day or 20 mg every other day.
  7. Patients who regularly use daytime oxygen therapy for more than one hour per day.
  8. Patients who have completed a pulmonary rehabilitation program in the six weeks prior to the screening visit (Visit 1) or patients who are currently in a pulmonary rehabilitation program
  9. Pregnant or nursing women
  10. Women of childbearing potential not using two effective methods of birth control (one barrier and one non-barrier).
  Contacts and Locations
Please refer to this study by its identifier: NCT00796653

  Show 98 Study Locations
Sponsors and Collaborators
Boehringer Ingelheim
Study Chair: Boehringer Ingelheim Boehringer Ingelheim
  More Information

No publications provided

Responsible Party: Boehringer Ingelheim, Study Chair, Boehringer Ingelheim Identifier: NCT00796653     History of Changes
Other Study ID Numbers: 1222.14, 2008-001934-28
Study First Received: November 21, 2008
Last Updated: May 4, 2011
Health Authority: Argentina: A.N.M.A.T. (Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica)
Brazil: National Health Surveillance Agency
Canada: Health Canada - Therapeutic Products Directorate
Czech Republic: State Institute for Drug Control (SUKL), CZ-100 41 Prague 10
Denmark: The Danish Medicines Agency
Finland: Finnish Medicines Agency
Germany: Federal Institute for Drugs and Medical Devices
Hong Kong: Department of Health
India: Drugs Controller General of India
Italy: Comitato Etico Centrale dell'IRCCS Fondazione Salvatore Maugeri di Pavia
Korea, Republic of: Korea Food and Drug Administration
Malaysia: Ministry of Health
Norway: Norwegian Medicines Agency (Statens Legemiddelverk)
Philippines: Department of Health
Romania: National Medicines Agency, Bucharest
Russia: Ministry of Healthcare and Social Development of Russian Federation, Moscow
South Africa: Medicines Control Council
Spain: Agencia Espanola del Medicamento y Productos Sanitarios
Sweden: Medical Products Agency Regional Ethics Committee of Umeå
Thailand: Ministry of Public Health

Additional relevant MeSH terms:
Chronic Disease
Lung Diseases
Respiration Disorders
Pulmonary Disease, Chronic Obstructive
Lung Diseases, Obstructive
Disease Attributes
Pathologic Processes
Respiratory Tract Diseases
Adrenergic beta-2 Receptor Agonists
Adrenergic beta-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Anti-Asthmatic Agents
Respiratory System Agents
Therapeutic Uses processed this record on April 16, 2014